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ELECTRONIC LETTER
Novel splice isoforms for NLGN3 and NLGN4 with possible
implications in autism
Z Talebizadeh, D Y Lam, M F Theodoro, D C Bittel, G H Lushington, M G Butler
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J Med Genet 2006;43:e21 (http://www.jmedgenet.com/cgi/content/full/43/5/e21). doi: 10.1136/jmg.2005.036897
Objective: To screen cDNA for NLGN3 and NLGN4 from
lymphoblastoid cells from autistic subjects.
Methods and results: 10 young autistic females and 30 non-
autistic subjects were studied for alterations in two X linked
genes, NLGN3 and NLGN4. A novel NLGN4 isoform
lacking exon 4, which occurred de novo on the paternal
allele, was identified in one of the autistic females.
Monoallelic expression of NLGN4 was seen in this subject
and in 11 of 14 informative autistic and non-autistic females
using a single nucleotide polymorphism found at 39 UTR.
Additionally, the NLGN3 transcript was present in two
isoforms (with and without exon 7) in nine of 10 autistic
females and in 30 non-autistic subjects, including parents of
the autistic female having only the complete transcript with
exon 7, and from the whole brain of a control. The novel
truncated NLGN3 product may have a regulatory role, as
reported in other proteins (for example, vasopressin recep-
tor) by attenuating the function of the full length isoform,
resulting in a reduction of the mature protein. Three
dimensional protein structures were characterised using
comparative modelling, and significant changes were
suggested in the protein cores for these two neuroligin
isoforms.
Conclusions: Splice variants may lead to potentially abnor-
mal neuroligins in the causation of autism spectrum
disorders.
A
utism (MIM 209850) is a genetically heterogeneous
early onset neurodevelopmental disorder with devel-
opmental difficulties noted by three years of age. It
belongs to a group of conditions known as autism spectrum
disorders (ASD), including classical autism, pervasive devel-
opmental disorder–not otherwise specified (PDD-NOS), and
Asperger syndrome. Diagnostic features for classical autism
include significant impairment in communication and social
interaction accompanied by a pattern of repetitive or
stereotypical behaviours and interests.1
To date, several candidate genes have been examined to
evaluate their possible associations with autism. These have
been selected on the basis of supporting linkage data,
cytogenetic evidence, or clinical presentation. The main
screening method for candidate genes is direct DNA
sequencing of exons and their flanking intronic regions
using genomic DNA from subjects with autism compared
with controls. The proposed candidate genes for autism
include the neuroligins which hold promise to uncover
molecular causes of this complex neurological disorder.
Neuroligins are adhesion proteins that bind to b-neurexin,
a cell surface protein, to form functional synapses.2
Neuroligins 1, 3, and 4 are localised to excitatory glutama-
tergic axons, while neuroligin 2 is localised to inhibitory
GABA axons.3 Neuroligins are composed of an extended N-
terminal extracellular region containing a large esterase-
homology domain necessary for the activity of neuroligins,
and a short cytoplasmic domain.2
The neuroligin 3 gene (NLGN3), localised to Xq13, is
composed of eight exons with the start codon in exon 2.4
Exons 7 and 8 are the largest exons, encoding about 65% of
the NLGN3 protein. A point mutation of NLGN3 (R451C) was
first reported in two affected brothers, one with typical
autism and the other with Asperger syndrome.5 This
mutation resulted in intracellular retention of the mutant
protein, causing loss of synaptic function.6
The fourth member of the neuroligin gene family, NLGN4,
localised to Xp22.3, is composed of six exons and has 63–73%
amino acid identity with other human neuroligin genes.7
Jamain et al5 identified a 1 base pair (bp) insertion
(1186insT) in the NLGN4 gene in two affected sons from a
Swedish family (one with autism and the other with
Asperger syndrome), resulting in a frame shift mutation
causing a premature termination (D396X). Later, a 2 bp
deletion in this neuroligin gene was reported in a large
French family including several male members affected by
non-specific X linked mental retardation, with or without
autism or PDD-NOS.8 Functional analysis showed that the
D396X frame shift mutation resulted in intracellular reten-
tion of the NLGN4 mutant protein and loss of synaptic
function.6
Recently, Chih et al2 reported additional data using
electrophysiological studies on mutant neuroligins carrying
deletions in either the cytoplasmic tail or in the esterase
homology domain which emphasised the critical role of the
neuroligin genes in maintaining a functional balance
between excitatory and inhibitory synapses in hippocampal
neurones. They concluded that neuroligin defects led to
selective loss of inhibitory function and abnormal excitatory/
inhibitory balance in neurones. Such a defect is believed to
play a role in autism.
Despite these positive findings, mutation screening of
neuroligins using genomic DNA from subjects with ASD
suggest that these mutations are not common or occur at a
low frequency in the autistic population.9–12 To further
investigate the role of neuroligins in autism, we screened
the NLGN3 and NLGN4 genes using cDNA generated from
actively growing lymphoblastoid cell lines from autistic
females and non-autistic males and females.
METHODS
Subjects
Our autistic group consisted of 10 females diagnosed with
classical autism (one from simplex and nine from multiplex
Abbreviations: AGRE, Autism Genetics Resource Exchange; ASD,
autism spectrum disorder; PDD-NOS, pervasive developmental
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families). These autistic females had skewed X chromosome
inactivation (that is, a ratio of .80:20) using the androgen
receptor gene,13 and were selected from a previous study on
X chromosome inactivation patterns in females with aut-
ism.14 The control group consisted of 30 subjects (12 female
and 18 male) without a history of autism or mental
retardation. Autistic subjects were ascertained from the
Autism Genetics Resource Exchange (AGRE), a publicly
available biomaterials repository located in Los Angeles. The
diagnosis of autism was established in the affected females
with the use of the Autism Diagnostic Interview–Revised
(ADI-R).1 Chromosome analysis and fragile X testing were
reportedly normal. DNA and clinical information (medical
and pedigree data, diagnostic assessments and scores) were
obtained on each subject from AGRE.
cDNA mutation screening
Total RNA was extracted from growing lymphoblastoid cell
lines. One microgram of total RNA was used to synthesise
cDNA using transcriptor reverse transcriptase kit from
Roche (Indianapolis, Indiana, USA). The entire coding
sequences of the NLGN3 and NLGN4 genes were amplified
using three pairs of primers for each one of these candidate
genes: NLGN3-244F 59-TGATGCTGTCACCCTGGAGTC-39
and NLGN3-1172R: 59-GGATGATGGCTCTCTGGAAAAG-39
generating a 929 bp polymerase chain reaction (PCR)
product;NLGN3-1049F 59-ATTGCCTTCTTCGGGGGAG-39 and
NLGN3-2037R: 59-TGGTCTCGGGGATTGTATTTG-39 generat-
ing a 989 bp PCR product; NLGN3-1884F 59-ATGTTATG-
CTCAGTGCTGTCGTC-39 and NLGN3-3005R: 59-GGGTTTGTT-
CAGGTTTACTTCCG-39 generating a 1122 bp PCR product;
NLGN4-184F 59-TTGTCCCTGGAGGTGTTGG-39 and NLGN4-
1458R 59-TGATGGTCTGCTGGATGAGC-39 generating a 1275
bp PCR product; NLGN4-832F 59-TGCTGCCCATCTGGTTT-
ACC-39 and NLGN4-1664R 59-GGACACGGAGAAGTCAAA-
GTCG-39 generating a 833 bp PCR product; and NLGN4-
1603F 59-TGGACGGCATCGTGGATAAC-39 and NLGN4-2946R
59-GCAGAGGGATAGGAAGGGAAATAG-39 generating a 1344
bp PCR product. In order to screen the intron/exon junction of
exon 4 in subject HI 1920, we amplified a fragment from
genomic DNA using intronic primers: exon 4-F 59-TTCAGTG-
AGAAAGACAGGCG-39 and exon 4-R 59-CAGAGCAAA-
TGGAACAAAAGC-39. We then sequenced the amplified
fragment with two internal primers (exon 4A-R 59-CGAGCC-
AAAGATGGTCACTC-39 and exon 4B-F 59-AAGCACTGCGG-
TGGATTG-39) to screen the splice junctions.
PCR was carried out in a total volume of 25 ml using
FailSafe PCR premix selection kit according to the manu-
facturer’s instructions (Epicentre, Madison, Wisconsin,
USA). The amplified products were run on a 2% agarose
gel, and the DNA bands were visualised by use of ethidium
bromide staining under ultraviolet light. For sequence
analysis, amplified products were purified using centrisep
columns (Princeton Separations, Adelphia, New Jersey,
USA). The purified PCR fragments were then sequenced
with capillary electrophoresis ABI 3100 sequencer (Applied
Biosystems, Foster City, California, USA). The primers for the
NLGN3 (NM_018977) and NLGN4 (NM_020742) genes were
designed using MacVector version 2.0 computer program
(ACCELRYS, San Diego, California, USA).
Single nucleotide polymorphism analysis and allelic
expression of NLGN4
PCR primers NLGN4-2515F (59-CGCTCCTCTTCCTCAACATC-
39) and NLGN4-3507R: (59-TCAGGCTGGCAAAACACTC-39)
were designed to amplify a 993 bp fragment containing the A/
Figure 1 A novel NLGN3 transcript lacking exon 7. Partial translation and nucleotide sequences of (A) the intact NLGN3 gene and (B) the truncated
NLGN3-exon 7 missing isoform. Amino acids encoded/ predicted by the representative nucleotides are shown below each electropherograms. The
intervening region contains 537 and 31 residues in the complete and truncated products, respectively.
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G polymorphism at position 3199 in the 39UTR. The forward
primer is located in the last coding exon and the reverse
primer is inside the untranslated region. The same primer
pair was used to amplify the corresponding region from both
genomic DNA and cDNA. An internal primer upstream of the
polymorphism position (NLGN4-3060F: 59-
AAAAGGCAGTCATCCCATCCCG-39) was used for DNA
sequencing. For females having two different alleles in their
genomic DNA (informative for the single nucleotide poly-
morphism (SNP)), the same region was amplified from cDNA
to determine allelic expression. To evaluate whether or not
exon 4 was present in the expressed allele for subject HI 1920,
the cDNA was amplified with forward and reverse primers,
NLGN4-832F and NLGN4-3507R, which span both the exon 4
and the SNP region. The amplified fragment of about 2.5 kb
size was then sequenced with NLGN4-832F primer (to verify
the presence of exon 4) and NLGN4-3060F (to screen for the
SNP).
Structural modelling
Comparative modelling was carried out in order to generate
approximate three dimensional structures for the esterase-
like domains of the NLGN3 (NCBI accession number
NM_018977) and the X linked NLGN4 (NM_020742)
through analogy to previously characterised human,15
mouse,16 and Pacific electric ray (Torpedo californica)17 acet-
ylcholinesterase crystal structures. To establish the under-
lying structural relations, we aligned the neuroligin
sequences to those of human, mouse, and Pacific electric
ray acetylcholinesterases with the Clustal-W program,18 using
the BLOSUM-30 substitution matrix,19 and standard gap
penalties of 10 for opening and 0.1 for extension. Portions of
Figure 2 A novel NLGN4 transcript lacking exon 4. The gel image illustrating the amplified product of the NLGN4 gene for an autistic subject (HI
1920) and other family members is shown in (A). The corresponding partial DNA sequencing for this autistic subject (HI 1920) generated from (B) the
top band and (C) the lower band is demonstrated. The smaller band reveals exon 4 skipping which results in an in-frame deletion of 62 amino acids.
Species Exon 4
Figure 3 Multiple protein alignment. Partial amino acid sequence alignment of the four members of the human neuroligin gene family (NLGN4,
NLGN3, NLGN2, NLGN1) and their homologous gene in mouse, rat, and chimpanzee corresponding to exon 4 in NLGN4. The human Y chromosome
homologue (NLGN4Y) sequence is also shown. Amino acids that differ from the human X linked form of NLGN4 (NLGN4) sequence are highlighted.
The conserved cysteine residue7 is marked by asterisks. The conserved glycine residue, thought to be aligned with the triad’s serine in cholinesterases,7
is marked by a vertical arrow.
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the NLGN3 and NLGN4 sequences that lay outside the
esterase-like domain (NLGN3 residues 1–37, 616–828;
NLGN4 residues 1–41, 602–816) were omitted from con-
sideration. Based on the resulting multiple sequence align-
ment, we used the Modeller program20 to predict the
corresponding three dimensional neuroligin structures by
fitting the aligned NLGN3 and NLGN4 sequences to a
consensus structural template derived from the three afore-
mentioned crystal structures. In the modelling process we
applied default restraint settings, and effected a rigorous
relaxation protocol involving five simulated annealing
relaxation cycles (4.4 ps stepwise warming from 0–1000 K,
followed by 19.2 ps stepwise cooling back down to 300 K, all
done through Charmm force field and charges).21 The
resulting structures were visualised and rendered in SYBYL
7.0 (The Tripos Associates, St Louis, Missouri, USA).
RESULTS
cDNA screening
The entire coding sequence of both NLGN3 and NLGN4 genes
were screened in 10 autistic females and 30 non-autistic
controls. In nine of the 10 autistic females, the NLGN3
transcript was present in two isoforms (with and without
exon 7), shown in fig 1. This novel isoform was predicted to
result in premature termination shortly after exon 6,
producing a truncated product. We identified these two
transcripts in both males and females using lymphoblastoid
cDNA from 30 non-autistic subjects including parents of the
autistic female not producing a transcript without exon 7
(subject ID: HI 0959) and a control female whole brain.
No mutations or polymorphisms were identified in the
coding sequences of the NLGN4 gene in the 10 autistic
females. However, when amplifying a fragment from cDNA
encompassing the middle section of the gene (from exon 2 to
exon 5), in one autistic female (subject ID: HI 1920) there
was evidence for the presence of a shorter fragment in
addition to the fragment of expected size (that is, a faint
band was seen below the band of expected size on the
agarose gel). To evaluate the presence of the second
unexpected band, this PCR product was reamplified
(fig 2A). The two fragments were excised from the gel and
their DNA isolated and sequenced separately. DNA sequen-
cing generated from both bands matched to NLGN4 but exon
4 was missing in the lower (smaller) band (fig 2, panels B
and C). The size difference between these two bands
corresponded to exon 4 (that is, 185 nt). When exon 4 and
its flanking intronic region (about 200 nt from each side) was
amplified and sequenced from the subject’s genomic DNA, no
changes were detected in the splice junctions. No other tissue
was available from subject HI 1920 to examine for the
presence of the NLGN4 transcript without exon 4.
The NLGN4 allele with the exon 4 skipping is predicted to
result in an in-frame exclusion of 62 amino acids. Protein
sequence alignment of the four members of the neuroligin
gene family (NLGN1–4) has demonstrated that amino acids
encoded by NLGN4 exon 4 are highly conserved among
different neuroligin proteins (fig 3). The NLGN4 transcript
lacking exon 4 was not found in lymphoblastoid cDNA from
any of the 30 non-autistic subjects including parents of
HI1920 screened in our study.
To investigate the parental origin of the allele with exon 4
skipping in autistic subject HI 1920, the 39 untranslated
region (39UTR) was screened for the presence of a poly-
morphism. One SNP (A/G) in NLGN4 was identified in the
genomic DNA at position 3199 in this autistic female with
exon 4 skipping. However, only one of the two alleles (G) was
detected when the same region was amplified from her cDNA
(fig 4). DNA sequencing using a primer upstream of exon 4
indicated the presence of this exon in the expressed G allele
in subject HI 1920. Monoallelic expression was also observed
in her unaffected sister except for the A allele. When other
family members were screened for this SNP, it was shown
that the maternal allele (G) was expressed in the autistic
female while only the paternal allele (A) was detected in her
unaffected sister (fig 4). Two other autistic families were
Figure 4 Single nucleotide
polymorphism (SNP) analysis and
monoallelic expression of the NLGN4
gene. Inheritance of the SNP found in
the 39 untranslated (39UTR) region of
the NLGN4 gene is illustrated for the
autistic female (HI 1920) with exon 4
missing allele, along with her parents
and unaffected sibling. DNA
sequencing from genomic DNA shows
the presence of two alleles in HI 1920
and her sister (HI 1919), while only one
of the two alleles (maternal and
paternal allele, respectively) was
detected in their cDNA. As shown in fig
2A, two products were polymerase
chain reaction (PCR) amplified for
subject HI 1920 after second
amplification. A weak signal
representing a smaller band was
present in the first PCR amplification
(data not shown). However, when a 2.5
kb size fragment encompassing both
exon 4 and the SNP was sequenced,
only one product was seen for subject
HI 1920. It should be noted that if a
second product (lacking exon 4) is
present but has an intensity of less than
10% it could not be observed in DNA
sequencing.
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screened for this SNP but no consistent pattern was observed
for the parental origin of the expressed allele. The monoallelic
expression of NLGN4 appears to be random and not caused
by imprinting.
Genomic DNA from a total of 25 females (affected and
unaffected) was screened for the SNP at the 39UTR of the
NLGN4 gene and 14 females (56%) were found heterozygous.
Eleven of 14 informative females (79%) displayed monoallelic
expression in their lymphoblastoid cDNA while the remaining
showed expression from both alleles. Furthermore, cDNA from
the frontal cortex, visual cortex, and pons were also available
for one of these informative non-autistic females for this SNP
(A/G). Monoallelic expression of the A allele was seen in her
frontal cortex and pons while both alleles were expressed in
her lymphoblastoid cells and visual cortex.
Using the most recent assembly (May 2004) from the
UCSC genome browser (http://genome.ucsc.edu), two RefSeq
accessions (NM_020742 and NM_181332) were identified for
NLGN4, known as variant 1 and variant 2, respectively. These
two NLGN4 variants encode the same protein as they differ
only in the 59UTR region. Furthermore, sequences for two
mRNA with alternative splice exons, AY358562 and
AX773938, have been found to match with NLGN4.
Sequence alignment between these mRNA and NM_020742
shows inclusion of 60 nt (before exon 3) and 112 nt (before
exon 4) in AY358562 and AX773938, respectively. The
primers used in our study flanked this region but no
alternative splicing was seen, as suggested by the UCSC
genome browser. For NLGN3, one RefSeq accession,
NM_018977, was found in the UCSC browser; however,
Philibert et al4 reported two transcripts for this gene. The
longer transcript (AF217411) consisted of sequences from all
exons except exon 3 and a shorter transcript (AF217412)
using exon 3 terminated in the poly A tail shortly before the
end of exon 7. We found transcripts with and without exon 3
in our study but our primers would not have picked up
products with premature termination in the poly A tail.
Structural modelling
Exploiting a reasonable level of sequence similarity between
the neuroligin esterase-like domains and acetylcholinester-
ase, a prior comparative modelling study was carried out to
predict the structure of human neuroligin 1.22 23 Strong
homology with human acetylcholinesterase also make
NLGN3 (33% identical, 62% similar) and NLGN4 (33%
identical, 63% similar) good candidates for such analysis,
offering reasonable expectations that the basic underlying
fold structure will be well represented, and that predicted
intra-chain interactions, if approximate, should generally be
qualitatively correct. There are two gaps of note in the
neuroligin/acetylcholinesterase alignments that should be
addressed: segments of 9 and 13 residues in NLGN4 and of
eight and 24 residues in NLGN3 for which there is no
analogous complement in the acetylcholinesterase templates.
In our predicted models, these gaps appear in surface regions
and, based on the simulated annealing structural relaxation,
appear to correspond to unstructured segments that should
have little effect on the fold structure. Taking all of this into
account, it is reasonable to assert that both NLGN3 and
NLGN4, depicted in fig 5, panels A and B, respectively,
correspond to three-layer (aba) sandwiches with the basic
Rossman fold topology characteristic of cholinesterases.
DISCUSSION
Except for the one autistic female, who only produced the
complete NLGN3 transcript (HI 0959), the truncated isoform
of NLGN3 was present in all subjects screened including the
parents of this autistic female. It therefore appears that the
truncated isoform is a normal product. However, this
truncated product may not have normal neuroligin activity
owing to the absence of an intact esterase domain involving
exons 7 and 8. The novel isoform lacking exon 7 would not
have been detected in the original description of NLGN3
which used a probe corresponding to exons 7 and 8.4
We suggest that this novel truncated NLGN3 product may
have a regulatory role in the activity of neuroligins by
attenuating the function of the full length isoform resulting
in a reduction of the mature protein. This potential regulatory
impact on the function of the complete transcript might be a
necessary factor in maintaining balance between excitatory/
inhibitory neurones. Similar attenuating regulatory mechan-
isms using splicing variants have been shown for other
proteins such as the vasopressin V2 receptor,
24 whereby two
alternatively spliced transcripts are generated. The protein
Figure 5 Predicted three dimensional structure for the esterase-like domains of the NLGN3 and NLGN4 proteins. (A) Comparative three dimensional
model of human NLGN3. Protein segment corresponding to exon 7 is rendered in green, with helices shown as cylinders and sheets as flat arrows.
Spatial extents of the putative EF-hand domain and important mutagenesis residues (K620, V621, H626, L627) are shown as red and blue line
surfaces, respectively. Remainder of the protein is rendered according to secondary structure features with magenta helices, yellow sheets, and grey
coils. (B) Comparative three dimensional model of human NLGN4. The protein segment corresponding to exon 4 is rendered in green, with helices
shown as cylinders and sheets as flat arrows. Spatial extents of the putative EF-hand domain and important mutagenesis residues (K586, V587, E592,
L593) are shown as red and blue line surfaces, respectively. The remainder of the protein is rendered according to secondary structure features with
magenta helices, yellow sheets, and grey coils.
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encoded by the small transcript (V2b splice variant) is
retained inside the cell while the longer wild type variant
(V2a) is found at the cell surface. Expression of the splice
variant V2b downregulates the surface expression of the V2a
receptor by forming V2aV2b heterodimers inside the cell.
24
Such a mechanism may occur in the regulation of NLGN3
function. We suggest that the absence of the truncated
product in our affected female resulting in only a full length
NLGN3 isoform may have contributed to her autism.
The recent reports of allelic variation in gene expression for
an unexpectedly large number of genes have shown that
preferential expression of one allele is common in the human
genome.25 Thus, unequal expression of two alleles may
contribute to human variability and may have implications
for disease susceptibility.25 26 For example, study of allelic
variation in gene expression for 602 genes in kidney and liver
tissues from seven individuals showed preferential expres-
sion of one allele (greater than twofold difference) in at least
one individual for 326 genes (54%). Furthermore, a sig-
nificant difference (greater than fourfold) between the
expression level of the two alleles was also observed for 170
of these studied genes (28%).26
In a recent paper published in Nature, a comprehensive X
inactivation profile of the human X chromosome genes was
generated using nine rodent/human somatic cell hybrid
fibroblast lines.27 In this hybrid system, expression of each
transcript was examined using PCR with reverse transcrip-
tion to determine if expression was detected only from hybrid
lines retaining the active X (that is, the gene is subject to
inactivation) or from both the active and inactive X hybrid
lines (that is, the gene escapes from inactivation). This study
showed that about 15% of X linked genes escaped inactiva-
tion, including NLGN4 which was expressed in all inactive X
hybrids (9/9). A quantitative assay based on expressed single
nucleotide polymorphisms was then used to evaluate allelic
expression of 94 genes in skin cells from 40 women with
complete skewing of X inactivation. This quantitative assay
showed a variable expression level from the inactive X (from
.75% to ,25% of the active X expression) even for genes
that escape from inactivation. Interestingly, only 12 of 20
genes expressed from all the inactive X hybrids (9/9) were
biallelically expressed in all samples. However, some of these
genes (5/20) that were assumed to escape inactivation were
biallelic in only some fibroblast samples, and three genes
were monoallelic in all samples. These data suggested a
significant allelic variation in levels of X linked gene
expression in females. Allelic expression was measured only
for a subset of genes that escape from inactivation, not
including NLGN4. Our allelic expression based on direct
sequencing of a SNP at 39UTR was not quantitative but
clearly suggested that, for the NLGN4 gene which is reported
to escape from inactivation,27 monoallelic expression can be
seen in lymphoblastoid cell lines as well as in brain tissue in
some females.
In our study, a novel splice variant of the NLGN4 gene
lacking exon 4 was detected in one autistic female and none
of the 30 non-autistic subjects. DNA sequencing of the
flanking intronic region of exon 4 in this autistic female did
not reveal any sequence changes. However, it is possible that
changes in a functionally important intronic region farther
away from the splice sites might be responsible for the
observed exon skipping. To evaluate this possibility, we
propose to examine the entire intronic sequence upstream of
this exon.
The possible functional implication of this novel NLGN4
isoform remains to be determined. However, findings in our
study suggest that this NLGN4 isoform may be contributing
to the autism in this affected female. First, NLGN4 exon 4
encodes for 62 residues containing two conserved amino
acids: G254 (a residue in the sequence position corresponding
to the catalytic serine in cholinesterases)7 and C259 (con-
served cysteine).7 Furthermore, exon 4 encodes part of the
highly conserved esterase-like domain which is necessary for
the activity of the neuroligins.2 Second, this isoform was not
seen in 30 non-autistic subjects including her unaffected
parents and sister. Third, SNP analysis indicated monoallelic
expression of maternal and paternal NLGN4 allele for this
autistic female and her unaffected sister, respectively, in
lymphoblastoid cells. DNA sequencing of the preferentially
expressed allele (maternal) in this autistic subject showed
the presence of exon 4. The intact paternal allele was
expressed in the unaffected sister. Thus it appears that exon
4 skipping occurred de novo in the paternal allele in this
autistic female. Fourth, the inconsistent expression pattern of
NLGN4 was seen in four different tissues including frontal
cortex, lymphoblastoid cells, pons, and visual cortex available
from one control female without autism. Therefore, we
suggest that if the NLGN4 allele lacking exon 4 is
preferentially expressed in the brain of this autistic subject
it may reduce functional activity of the encoded NLGN4
protein and contribute to her autism.
Neuroligins are cell surface proteins with high binding
affinity to b-neurexins. A striking feature of the neurexin
genes is that thousands of neurexin proteins may be
synthesised from only three genes through the use of two
alternative promoters and alternative splicing.28 29 The exten-
sive alternative splicing of the neurexins may be functionally
important and play a regulatory role in controlling their
interactions with ligands.29 Thus it is not surprising to see
another layer of gene expression regulation (that is, mono-
allelic expression) existing for NLGN4, a member of the
neuroligin gene family.
In the cases of both NLGN3 and NLGN4, our structural
models predict that the segments corresponding to the
alternate splices of interest to this work (exon 7 in NLGN3
and exon 4 in NLGN4) participate in both surface and core
structural roles. In the core region, the splice segments
comprise a part of the central b sheet and also entail at least
one embedded helix. From modelling alone, it is difficult to
quantify precisely the impact of an alternate splice on the
overall protein structure; however, the presence of splice
segment elements within the protein core effectively guar-
antees that an alternate splice missing these elements would
show an adjusted fold as required for structural equilibrium
in a polar medium. Furthermore, it appears that the splice
segments in both NLGN3 and NLGN4 impinge on regions
important to neuroligin synaptogenic function. We find in
both cases that the splice segment borders directly on a
cluster of residues (blue line surface, corresponding to K620 +
V621 + H626 + L627 for NLGN3; and K586 + V587 + E592 +
L593 for NLGN4) identified through mutagenesis studies as
being critical to synaptogenesis.30 The splice segments also
appear to affect a sequence motif that has been identified as a
putative EF-hand structure (red line surface)—a prevalent
Ca2+ binding motif in cytoplasmic proteins that has also been
identified in extracellular species31 and has thus been
suggested as a possible site for Ca2+ mediated protein–protein
binding in neuroligins.22 These EF-hand domains appear to
manifest themselves in our predicted neuroligin structures as
highly electronegative patches arising from a convergence of
hydroxy and carboxy side chains: D362, T370, D373, S377,
and D381 in the case of NLGN3; and D344, D353, D355, S357,
and S359 for NLGN4. In the case of NLGN4, the splice
segment closely borders the putative EF-hand, and in the
NLGN3 case, the entire motif is incorporated as a subset of
the splice segment. The cumulative structural evidence
therefore suggests that the absence of exon 4 segment of
NLGN4 would have a substantial effect on the protein’s basic
6 of 7 Electronic letter
www.jmedgenet.com
 on 28 September 2007 jmg.bmj.comDownloaded from 
function and that an even greater effect is likely for NLGN3 in
the absence of its exon 7.
Conclusions
Our study suggests that other forms of genetic alteration
(other than mutations) including splice variants may lead to
potentially abnormal function of neuroligins in autism
spectrum disorder. Using different screening strategies with
the evaluation of transcripts instead of genomic sequencing
alone may shed light on changes in neuroligin function.
Based on preliminary examination of clinical data available
from AGRE, no unusual features were found in the two
autistic females with the specific neuroligin splice variants
compared with the other subjects we examined. Additional
studies are under way to characterise these splicing variants
further, along with the frequency with which they are found
in ASD subjects.
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